CN102435734A - Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application - Google Patents
Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application Download PDFInfo
- Publication number
- CN102435734A CN102435734A CN2011102660411A CN201110266041A CN102435734A CN 102435734 A CN102435734 A CN 102435734A CN 2011102660411 A CN2011102660411 A CN 2011102660411A CN 201110266041 A CN201110266041 A CN 201110266041A CN 102435734 A CN102435734 A CN 102435734A
- Authority
- CN
- China
- Prior art keywords
- ovarian cancer
- minutes
- tissue
- primary
- samples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 73
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 70
- 230000035945 sensitivity Effects 0.000 title claims abstract description 13
- 238000011156 evaluation Methods 0.000 title claims abstract 6
- 238000002512 chemotherapy Methods 0.000 title abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 46
- 238000006243 chemical reaction Methods 0.000 claims abstract description 42
- 102000053196 Xeroderma Pigmentosum Group D Human genes 0.000 claims abstract description 33
- 108700031763 Xeroderma Pigmentosum Group D Proteins 0.000 claims abstract description 33
- 101100226017 Dictyostelium discoideum repD gene Proteins 0.000 claims abstract description 32
- 101150105460 ERCC2 gene Proteins 0.000 claims abstract description 32
- 229940044683 chemotherapy drug Drugs 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- 238000001514 detection method Methods 0.000 claims abstract description 9
- 238000012216 screening Methods 0.000 claims abstract description 5
- 239000002246 antineoplastic agent Substances 0.000 claims abstract 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 83
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 238000012360 testing method Methods 0.000 claims description 22
- 239000000758 substrate Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 13
- 239000008096 xylene Substances 0.000 claims description 13
- 240000003291 Armoracia rusticana Species 0.000 claims description 12
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 12
- 108090000790 Enzymes Proteins 0.000 claims description 12
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012153 distilled water Substances 0.000 claims description 11
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000000427 antigen Substances 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 238000011161 development Methods 0.000 claims description 8
- 239000008363 phosphate buffer Substances 0.000 claims description 7
- 210000002966 serum Anatomy 0.000 claims description 7
- 239000000243 solution Substances 0.000 claims description 7
- 238000010186 staining Methods 0.000 claims description 7
- 239000008399 tap water Substances 0.000 claims description 7
- 235000020679 tap water Nutrition 0.000 claims description 7
- 239000007979 citrate buffer Substances 0.000 claims description 6
- 230000018044 dehydration Effects 0.000 claims description 5
- 238000006297 dehydration reaction Methods 0.000 claims description 5
- 238000011534 incubation Methods 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 239000013642 negative control Substances 0.000 claims description 4
- 239000012188 paraffin wax Substances 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 3
- 229930012538 Paclitaxel Natural products 0.000 claims description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 3
- 229960004316 cisplatin Drugs 0.000 claims description 3
- 229960001592 paclitaxel Drugs 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 3
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000006911 enzymatic reaction Methods 0.000 claims description 2
- 239000012224 working solution Substances 0.000 claims 8
- 230000000903 blocking effect Effects 0.000 claims 7
- 101100298998 Caenorhabditis elegans pbs-3 gene Proteins 0.000 claims 5
- 108010090804 Streptavidin Proteins 0.000 claims 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 102000003992 Peroxidases Human genes 0.000 claims 2
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 239000012154 double-distilled water Substances 0.000 claims 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 238000009877 rendering Methods 0.000 claims 1
- 239000012192 staining solution Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 17
- 201000011510 cancer Diseases 0.000 abstract description 8
- 230000002980 postoperative effect Effects 0.000 abstract description 7
- 238000003759 clinical diagnosis Methods 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 5
- 238000011160 research Methods 0.000 abstract description 5
- 206010059866 Drug resistance Diseases 0.000 abstract 1
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 238000006395 oxidase reaction Methods 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 51
- 210000004027 cell Anatomy 0.000 description 49
- 239000012530 fluid Substances 0.000 description 21
- 235000019441 ethanol Nutrition 0.000 description 20
- 238000004043 dyeing Methods 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- 230000006287 biotinylation Effects 0.000 description 8
- 238000007413 biotinylation Methods 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 238000002372 labelling Methods 0.000 description 8
- 239000000975 dye Substances 0.000 description 7
- 238000007789 sealing Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 229930040373 Paraformaldehyde Natural products 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- 229920002866 paraformaldehyde Polymers 0.000 description 6
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 238000011010 flushing procedure Methods 0.000 description 5
- HLUCICHZHWJHLL-UHFFFAOYSA-N hematein Chemical compound C12=CC=C(O)C(O)=C2OCC2(O)C1=C1C=C(O)C(=O)C=C1C2 HLUCICHZHWJHLL-UHFFFAOYSA-N 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 206010027336 Menstruation delayed Diseases 0.000 description 4
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000003560 cancer drug Substances 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000004321 preservation Methods 0.000 description 4
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002055 immunohistochemical effect Effects 0.000 description 3
- 238000003364 immunohistochemistry Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 244000050510 Cunninghamia lanceolata Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 102100034135 Activin receptor type-1C Human genes 0.000 description 1
- 101710173005 Activin receptor type-1C Proteins 0.000 description 1
- 102100036597 Basement membrane-specific heparan sulfate proteoglycan core protein Human genes 0.000 description 1
- 101000834245 Danio rerio Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 210000004276 hyalin Anatomy 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 108010049224 perlecan Proteins 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 238000011248 postoperative chemotherapy Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000004999 sex organ Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6875—Nucleoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4703—Regulators; Modulating activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
An ovarian cancer primary chemotherapy sensitivity evaluation kit and application thereof, wherein the kit comprises a confining liquid, an antigen-antibody reaction system, an avidin-oxidase reaction system and a counterstain. The invention of the present application is based on the correlation between the expression level of ERCC2 in serous ovarian cancer cells/tissues and the sensitivity of cells, tissues or tumor patients as hosts to primary chemotherapeutic drugs. Can realize multiple purposes such as chemotherapy sensitivity/drug resistance evaluation, tumor patient screening, primary chemotherapy drug tolerance evaluation and the like through ERCC2 detection. The method is simple and accurate, has low requirements on samples, and can be used for large-scale screening or retrospective research. When the kit is used for clinical diagnosis and medication guidance, in-vitro cancer tissues of a patient after an operation are collected for detection, and non-invasive, painless and non-invasive detection is realized, so that the kit is very easy to accept by the patient, is beneficial to prolonging the life of the patient, relieves the pain of chemotherapy of the patient, and improves the postoperative life quality of the patient.
Description
Technical field
The present invention relates to a kind of kit of the chemotherapy in ovarian cancer susceptibility that is used for testing and assessing and screen at former chemotherapy sensitivity/resistance test and appraisal, tumor patient, and the application of former chemotherapeutics tolerance assessment.
Background technology
(Epithelial Ovarian Cancer is one of common tumour of female sex organ EOC) to the epithelial ovarian cancer, is the primary killer in the female tumor.Wherein the serosity cancer is the most common, accounts for 80～85% of all oophoromas in western countries, is divided into late period with early stage, and its middle and advanced stage accounts for the overwhelming majority, very rarely account in early days all ovaries＜5%.Think now early, late period the serosity cancer be that two kinds of oophoroma are dissimilar, in fact its morphologic difference has reflected oncobiology difference, is the difference of gene level after all.This disease is difficult for diagnosis in early days, and patient had missed best occasion for the treatment when went to a doctor late period.Because the oophoroma end-stage patients have diffusion in various degree, so patient's postoperative must carry out chemotherapy at once.In the world ovarian cancer post operation patient's chemotherapy regimen mainly is divided at present: downpayment complementary (adjuvant; With platinum is the cis-platinum or the carboplatin/taxol on basis) and later stage rescue property (salvage; Multiple chemotherapeutics compatibility) treatment.Because patient's Gene regulation is different; Its developed by molecule level is also different, thus different to the susceptibility of former chemotherapeutics, thereby be that basic downpayment adjuvant chemotherapy does not have any alleviation concerning 40～50% patients' symptom with platinum; Also claim former resistance; Because treatment does not have specific aim, stopped over best chemotherapy period, be to cause one of dead fast reason of patient.Therefore, predict the susceptibility of patient before the chemotherapy to former chemotherapeutics, most important to the life that prolongs ovarian cancer patients.
On the other hand, the method according to tissue morphology classification is divided into four different histological type with the epithelial ovarian cancer for a long time, that is: serosity, and endometrial-like, mucus and hyaline cell property, wherein common with serosity again.But clinical practice is found; Only organize the typoiogical classification standard that oophoroma is classified according to tradition; Its pathological characters of further research and guiding clinical diagnosis and treatment there are deficiency more, therefore also need a kind of method the tumour under the traditional taxonomy item is further screened and to classify urgently.
Moreover as previously mentioned, the clinical medicine that is used to treat oophoroma does not have any alleviation to quite a few patient's symptom, but this need just can come to light through one quite long clinical period, tends to cause the delay treatment chance, increases less patient suffering.Therefore, also need a kind of fast and effectively high-throughput screening method in the drug development research, come the possible tolerance risk of former chemotherapeutics in the clinical treatment oophoroma of assessment objective pointedly.
Summary of the invention
Find in present inventor's research; The expressing quantity of ERCC2 is higher more than 2 times than mdr cell in sensitive cells; In conjunction with this discovery; The inventor utilizes China's oophoroma patient specimen, adopts simple immunohistochemical method, has confirmed the biomarker effect of ERCC2 the chemotherapy in ovarian cancer patient qualitatively.
Based on above-mentioned result of study; One of the object of the invention is to provide a kind of chemotherapy in ovarian cancer susceptibility test and appraisal kit; Described kit comprises: the confining liquid of being made up of the phosphate buffer of 5% lowlenthal serum, 1%BSA, 0.01% Triton X-100 and pH7.4; The antigen-antibody reaction system that forms by ERCC2 antibody (1: 1000), biotinylation two anti-working fluids and confining liquid; Avidin-oxide enzymatic reaction system of forming by horseradish enzyme labeling strepto-avidin working fluid and DAB reagent damping fluid, and as the haematine of counterstain.
In the embodiment preferred, described kit also comprises the antigen retrieval system that is made up of 0.01M citrate buffer and phosphate buffer, and the elimination endogenous peroxydase system that is made up of 3% hydrogen peroxide and phosphate buffer.Said kit can be applicable to paraffin-embedded ovarian cancer tissue sample pointedly.
Two of the object of the invention is to provide a kind of method of ovarian cancer tissue's sample to former chemotherapy drug susceptibility of testing and assessing; It is characterized in that using the described kit of claim 1; After comprising the steps: to use confining liquid to handle testing sample; Use ERCC2 antibody and biotinylation two anti-working fluids to carry out anti-and two anti-reactions respectively, use horseradish enzyme labeling strepto-avidin working fluid to handle sample then, carry out DAB colour developing and haematoxylin redyeing at last; Dyeing situation is per sample judged the susceptibility to former chemotherapeutics: the sample that is the brown positive reaction is judged to be the ovarian cancer tissue to former chemotherapy medicament sensitive; The sample that is blue look negative reaction is judged to be the ovarian cancer tissue to former chemotherapeutics tolerance.
Above-mentioned test and appraisal ovarian cancer tissue sample more specifically comprises the steps: the method for former chemotherapy drug susceptibility
1. sealing: the tissue at pending sample adds 200 μ l confining liquids, incubated at room 60 minutes;
2. antigen-antibody reaction:
(1) one anti-hatching: add the ERCC2 antibody of 150 μ l organizationally, cover tissue,, clean 3 times each 10 minutes then with PBS in 4 ℃ of incubated overnight to seal film according to 1: 100 dilution proportion;
If negative control group is used with the volume confining liquid to replace ERCC2 antibody.
(2) two anti-hatching: add 150 μ l biotinylations, two anti-working fluids organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
3. drip horseradish enzyme labeling strepto-avidin working fluid (S-A/HRP) organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
4. DAB colour developing:
(1) preparation substrate mixed liquor: in the distilled water of 1ml pH value=7.0, add a reagent A, after mixing, reagent B and reagent C respectively one be added dropwise to wherein, mix the substrate mixed liquor;
(2) colour developing: 150 μ l substrate mixed liquors are dripped organizationally color development at room temperature 3～10 minutes, fully colour developing back tap water flushing cessation reaction;
5. dye, dehydration, transparent, mounting: histotomy is immersed the haematine dye liquor 2 times, each 2 seconds; Handle 3 times each 5 minutes then with distilled water; Respectively handle 1 time each 1 minute more successively with 50% ethanol, 70% ethanol, 90% ethanol; Handle 2 times with absolute ethyl alcohol again, each 2 minutes, 1: 1 mixture process of xylene and absolute ethyl alcohol 1 time, 2 minutes, l00% xylene processing 2 times, each 2 minutes; Use gummy mounting at last, preserve;
6. dyeing situation is per sample judged the susceptibility to former chemotherapeutics: the sample that is the brown positive reaction is judged to be the ovarian cancer tissue to former chemotherapy medicament sensitive; The sample that is blue look negative reaction is judged to be the ovarian cancer tissue to former chemotherapeutics tolerance.
Be applicable to the tumor tissue in vitro or the cell sample of any kind on the theoretical method of test and appraisal ovarian cancer tissue sample to former chemotherapy drug susceptibility of the invention described above; Comprise ovarian cancer tissue, the formalin fixed FFPE ovarian cancer tissue of fresh collection, the freezing ovarian cancer tissue of OCT embedding, the fresh nothing that liquid nitrogen is preserved is ovarian cancer tissue etc. fixedly.No matter be applied to the biological specimen of which kind of type, those skilled in the art can confirm the pre-treating method of sample according to prior art information, made sample after the processing be applicable to according to the invention and SABC detect.Several kinds of typical samples and disposal route thereof are respectively:
When (1) said test and appraisal ovarian cancer tissue sample is applied to the test and appraisal of oophoroma formalin fixed paraffin-embedded tissue to the method for former chemotherapy drug susceptibility, The pretreatment is comprised the steps:
A. dewaxing: the conventional section of oophoroma formalin fixed paraffin-embedded tissue, the paraffin organization section of thickness 4～5 μ m is successively through 100% xylene dewaxing 3 times, each 5 minutes; Absolute ethyl alcohol dewaxing 3 times, each 2 minutes; 95% ethanol, 90% ethanol, 70% ethanol, 50% ethanol respectively dewax 1 time, 2 minutes;
B. antigen retrieval: carry out antigen retrieval with the 0.01M citrate buffer, clean 3 times each 5 minutes then with PBS;
C. eliminate endogenous peroxydase: histotomy is placed 3% hydrogen peroxide, and incubated at room 30 minutes is cleaned 3 times each 5 minutes with PBS.
Handling the gained sample directly is used for detecting.
When (2) said test and appraisal ovarian cancer tissue sample is applied to the test and appraisal of ovarian cancer tissue of freezing preservation of OCT embedding to the method for former chemotherapy drug susceptibility, The pretreatment is comprised the steps:
A. fixation of tissue: the about 2x2cm of fresh tumor tissues of excision when the oophoroma patient is performed the operation
3Insert immediately in 4% paraformaldehyde, 4 ℃, fixing 24 hours;
B.PBS cleans 3 times, each 10 minutes;
C. will organize and immerse 30% sucrose, 4 ℃ are spent the night;
D.OCT potpourri (opti-mum cutting temperature compound) embedding is placed on the dry ice;
E. after treating that the OCT potpourri solidifies, cryostat frozen section 7～10um;
Said test and appraisal ovarian cancer tissue sample is applied to fresh nothing that liquid nitrogen preserves fixedly during ovarian cancer tissue to the method for former chemotherapy drug susceptibility, and The pretreatment is comprised the steps:
A. the fresh tumor tissues of oophoroma patient excision is inserted rapidly in the liquid nitrogen, for use;
B. the time spent at first will be organized and immersed in 4% paraformaldehyde, and 4 ℃, fixing 24 hours;
According to the laboratory equipment that the user had, any in feasible above-mentioned two kinds of methods: promptly after FFPE or the OCT embedding process, handle the gained sample and directly be used for detecting.
The purpose of another aspect of the present invention provides the method for a kind of screening to the ovarian cancer patients of former chemotherapy medicament sensitive; This method also need be used the described chemotherapy in ovarian cancer susceptibility test and appraisal of the invention described above kit; Comprise the steps: that with the ovarian cancer patients tumor tissue in vitro be test sample; After using confining liquid to handle testing sample; Use ERCC2 antibody and biotinylation two anti-working fluids to carry out anti-and two anti-reactions respectively, use horseradish enzyme labeling strepto-avidin working fluid to handle sample then, carry out DAB colour developing and haematoxylin redyeing at last; The ovarian cancer patients that dyeing situation is per sample judged sample source is to former chemotherapy drug susceptibility: the sample that is the brown positive reaction is judged to be the ovarian cancer tissue to former chemotherapy medicament sensitive, and the ovarian cancer patients of sample source is to former chemotherapy medicament sensitive; The sample that is blue look negative reaction is judged to be the ovarian cancer tissue to former chemotherapeutics tolerance, and the ovarian cancer patients of sample source tolerates former chemotherapeutics.
The purpose of further aspect of the present invention provides a kind of method that is used to instruct the downpayment chemotherapy medication of ovarian cancer post operation patient; Comprise clinical collection patient ovarian cancer tissue, carry out SABC and detect and judge, confirm step such as therapeutic regimen, be in particular according to judged result:
I. sample collecting
II. the sample SABC detects and result's judgement
1. sealing: the tissue at pending sample adds 200 μ l confining liquids, incubated at room 60 minutes;
2. antigen-antibody reaction:
(1) one anti-hatching: add the ERCC2 antibody of 150 μ l organizationally, cover tissue,, clean 3 times each 10 minutes then with PBS in 4 ℃ of incubated overnight to seal film according to 1: 100 dilution proportion;
If negative control group is used with the volume confining liquid to replace ERCC2 antibody.
(2) two anti-hatching: add 150 μ l biotinylations, two anti-working fluids organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
3. drip horseradish enzyme labeling strepto-avidin working fluid (S-A/HRP) organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
4. DAB colour developing:
(1) preparation substrate mixed liquor: in the distilled water of 1ml pH value=7.0, add a reagent A, after mixing, reagent B and reagent C respectively one be added dropwise to wherein, mix the substrate mixed liquor;
(2) colour developing: 150 μ l substrate mixed liquors are dripped organizationally color development at room temperature 3～10 minutes, fully colour developing back tap water flushing cessation reaction;
5. dye, dehydration, transparent, mounting: histotomy is immersed the haematine dye liquor 2 times, each 2 seconds; Handle 3 times each 5 minutes then with distilled water; Respectively handle 1 time each 1 minute more successively with 50% ethanol, 70% ethanol, 90% ethanol; Handle 2 times with absolute ethyl alcohol again, each 2 minutes, 1: 1 mixture process of xylene and absolute ethyl alcohol 1 time, 2 minutes, 100% xylene processing 2 times, each 2 minutes; Use gummy mounting at last, preserve;
6. dyeing situation is per sample judged the susceptibility to former chemotherapeutics: the sample that is the brown positive reaction is judged to be the ovarian cancer tissue to former chemotherapy medicament sensitive; The sample that is blue look negative reaction is judged to be the ovarian cancer tissue to former chemotherapeutics tolerance.
III. interpretation of result and medication guide scheme determination
According to the testing result of Step II, it is high that the source patient of ovarian cancer tissue that can the preliminary judgement positive reaction treats responsive probability to former chemotherapeutics of postoperative; The source patient of the ovarian cancer tissue of negative reaction is high to former chemotherapeutics treatment of postoperative tolerance probability.For the latter, need show to confirm suitable postoperative chemotherapy scheme according to patient physiological pathology characteristic and clinical symptoms thereof.
Former the chemotherapeutics that reaches described in above-mentioned all methods of the present invention is meant and is used for the ovarian cancer post operation patient at the downpayment chemotherapeutics of implementing chemotherapy that this type medicine comprises platinum class, taxol or the combination of the two in the clinical practice.
Described in the technique scheme of the present invention and oophoroma or tumour be meant serous ovarian cancer late period.
The present inventor found expression and cell, the tissue of ERCC2 in tumour cell, especially the serous ovarian cancer cell/tissue or as host's tumor patient to the relevance between former the chemotherapy drug susceptibility.Although existing record about the ERCC2 method for immunohistochemical detection in the prior art, the definite relation between above-mentioned the two are never disclosed, the also unprecedented any teachings of institute in the prior art.Find that based on this application provides a series of methods that are used to judge former chemotherapeutics tolerance, and relevant agent combination.These methods can be applied to multiple sample, and frozen tissue, paraffin-embedded tissue, fresh in vitro tissue etc. can provide multi-level detection information, and the research that can be oophoroma provides support, and also for clinical diagnosis and direction of medication usage dependable detection index is provided.Method of the present invention is simply accurate, and less demanding to sample can be used for extensive examination or retrospective study.When being used for clinical diagnosis and medication guide, the stripped cancer tissue of gathering patients after surgery detects, do not have wound, painless, do not have invasive detection, patient very easily accepts.And visual result is prone to see, rapid sensitive, and is economical and practical.The selection that reasonably is applied to clinical application also helps to prolong patient's life, and the chemotherapy of alleviating patient is painful, improves patient's postoperative life quality.
Description of drawings
Accompanying drawing 4 width of cloth of the present invention:
Fig. 1 embodiment of the invention 1 tissue staining to be detected is example as a result, a wherein, and e=100 *; B, f=200 *; C, g=400 *; D, h=1000 *;
Be ERCC2 serous ovarian cancer postoperative resistance and responsive downpayment chemotherapy patients's expression figure late: the responsive patient's of chemotherapy cancerous tissue epithelium presents tawny positive reaction (shown in the arrow); Chemotherapy resistance patient's cancerous tissue epithelium presents blue look negative reaction (shown in the arrow).The responsive patient of CR=chemotherapy; IR=chemotherapy resistance patient; Enlargement factor: a, e=100X; B, f=200X; C, g=400X; D, h=1000X;
Fig. 2 and Fig. 3 are the gel electrophoresis figure and the statistic analysis result of the expressing quantity of ERCC2 among oophoroma sensitive cells OV2008 and the ovarian cancer drug-resistant cell C13 among the embodiment 2.
Fig. 4 be the immunofluorescence of oophoroma sensitive cells OV2008 and ovarian cancer drug-resistant cell C13 among the embodiment 2 detect (b, e) and immunohistochemical reaction (c, f) testing result figure.
Embodiment
As do not have specified otherwise, the solvent compound method described in the present invention is:
0.01M citrate buffer: the 0.885g citrate is dissolved in the 300ml distilled water, add 94.5 μ l glacial acetic acid adjust pHs to 6.0; Wherein, citrate is available from Tianjin Kermel Chemical Reagent Co., Ltd., batch number: 20070621;
Phosphate buffer (PBS): with 8g sodium chloride, 0.2g potassium chloride, 3.62g sodium hydrogen phosphate (12H
2O) and the 0.24g potassium dihydrogen phosphate dissolve in the 800ml distilled water watery hydrochloric acid adjust pH to 7.4, constant volume 1L;
Sealing damping fluid: 5% lowlenthal serum, 1% bovine serum albumin, pH 7.4 phosphate buffers, 0.01% Triton X-100 (tirtonX-100);
5% lowlenthal serum is available from U.S. ZYMED company, 1091950;
1%BSA is available from U.S. ROCHE, 10735078001;
0.01% Triton X-100 (tirtonX-100) is available from U.S. ROCHE, 0694;
ERCC2 one is anti-available from U.S. Protein Tech Group, Inc., 10818-AP;
Biotinylation two anti-working fluids, horseradish enzyme labeling strepto-avidin working fluid, reagent A (concentrating damping fluid 20x), reagent B (concentrating DAB damping fluid 20x) and reagent C (concentrating hydrogen peroxide damping fluid 20x) all derive from the SABC kit; Available from U.S. ZYMED company, SP-9000;
Triton X-100 (Triton-X 100) is available from Amersco, Cat#0694;
Bovine serum albumin (BSA) is available from Roche, Cat#10735078001;
Other medicine or reagent are analyzes pure level.
Following non-limiting example can make those of ordinary skill in the art more fully understand the present invention, but does not limit the present invention in any way.
I. collection of specimens
Gather 71 examples and organize the paraffin sample by the serous ovarian cancer that pathology department of Dalian Maternity Hospital preserves; Comfortable this hospital of these sample sources carries out radical excision operation serous ovarian cancer patient; Before sample is preserved through routine clinical tissue treatment: i.e. 10% formalin fixed; FFPE, room temperature preservation.
II. sample pre-service comprises the steps:
A. dewaxing: the conventional section of oophoroma formalin fixed paraffin-embedded tissue, the paraffin organization section of thickness 4～5 μ m is successively through 100% xylene dewaxing 3 times, each 5 minutes; Absolute ethyl alcohol dewaxing 3 times, each 2 minutes; 95% ethanol, 90% ethanol, 70% ethanol, 50% ethanol respectively dewax 1 time, 2 minutes;
B. antigen retrieval: carry out antigen retrieval with the 0.01M citrate buffer, clean 3 times each 5 minutes then with PBS;
C. eliminate endogenous peroxydase: histotomy is placed 3% hydrogen peroxide, and incubated at room 30 minutes is cleaned 3 times each 5 minutes with PBS.
III. SABC detects
1. sealing: the tissue at pending sample adds 200 μ l confining liquids, incubated at room 60 minutes;
2. antigen-antibody reaction:
(1) one anti-hatching: add the ERCC2 antibody of 150 μ l organizationally, cover tissue,, clean 3 times each 10 minutes then with PBS in 4 ℃ of incubated overnight to seal film according to 1: 100 dilution proportion;
If negative control group is used with the volume confining liquid to replace ERCC2 antibody.
(2) two anti-hatching: add 150 μ l biotinylations, two anti-working fluids organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
3. drip horseradish enzyme labeling strepto-avidin working fluid (S-A/HRP) organizationally, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
4. DAB colour developing:
(1) preparation substrate mixed liquor: in the distilled water of 1ml pH value=7.0, add a reagent A, after mixing, reagent B and reagent C respectively one be added dropwise to wherein, mix the substrate mixed liquor;
(2) colour developing: 150 μ l substrate mixed liquors are dripped organizationally color development at room temperature 3～10 minutes, fully colour developing back tap water flushing cessation reaction;
5. dye, dehydration, transparent, mounting: histotomy is immersed the haematine dye liquor 2 times, each 2 seconds; Handle 3 times each 5 minutes then with distilled water; Respectively handle 1 time each 1 minute more successively with 50% ethanol, 70% ethanol, 90% ethanol; Handle 2 times with absolute ethyl alcohol again, each 2 minutes, 1: 1 mixture process of xylene and absolute ethyl alcohol 1 time, 2 minutes, 100% xylene processing 2 times, each 2 minutes; Use gummy mounting at last, preserve;
IV. dyeing situation is per sample judged the susceptibility to former chemotherapeutics: the sample that is brown positive reaction (being the IHC stained positive) is judged to be the ovarian cancer tissue to former chemotherapy medicament sensitive, and the sample that is blue look negative reaction (being that IHC dyeing is negative) is judged to be the ovarian cancer tissue to former chemotherapeutics tolerance.Accompanying drawing 1a～d is the tissue staining photo as a result with typical positive reaction, and the visible tissue epithelium presents obvious tawny; Accompanying drawing 1e～h is the tissue staining photo as a result with typical negative reaction, and the visible tissue epithelium presents obvious blue.
Will be according to routine clinical diagnosis and treatment index gained judged result and the contrast of IHC coloration result, the validity of statistical study the inventive method is like V.
V. testing result and analysis:
According to the routine clinical diagnosis and treatment index of oophoroma chemotherapy of patients prognosis, in the 71 routine patient samples, 44 routine samples are judged to be former chemotherapy medicament sensitive type, and 27 examples are judged to be former chemotherapeutics tolerance type.Judge that concrete grammar is following:
Tumor patient to above-mentioned 71 routine sample sources carries out Information Statistics; Detection level according to patient's postoperative change of serum C A125 in the time of 6 months; Whether the situation of following up a case by regular visits in conjunction with chemotherapy also has new swollen thing to occur such as in 6 months, swollen thing diameter; Whether have continuation abdominal distension, stomachache, lose the appetite, become thin, weak etc. shows that the course of disease still in the clinical symptoms of progress, is divided into two types with patient:
1. chemotherapy responsive type: all measurable disease symptomses with assessment disappear, perhaps in the chemotherapy of patients 6 months the CA125 detection level be lower than＜30U/ml), new swollen thing is less than 3cm
3
2. chemotherapy resistance type: after 6 months chemotherapy, CA125 detects and still is higher than 30U/ml, and with showing the course of disease still in the clinical symptoms of progress, new swollen thing is greater than 3cm
3
Above-mentioned routine clinical index is judged as in the 44 routine samples of chemotherapy responsive type, and 34 examples (account for detect sample 73.3%) sample is judged to be IHC stained positive (to former chemotherapy medicament sensitive), and 11 examples (account for detect sample 26.7%) show that IHC dyeing is negative.
Above-mentioned routine clinical index is judged as in the 27 routine samples of chemotherapy tolerance type, and 19 examples (account for detect sample 70.4%) sample is judged to be IHC dyeing negative (to former chemotherapeutics tolerance), and 8 examples (account for detect sample 29.6%) show the IHC stained positive.
Through statistical results show; Result and contrast method judged result there was no significant difference that IHC dyeing is judged; Explanation is with method of the present invention, and promptly above-mentioned IHC colouring method can carry out the somatotype of former accurately chemotherapeutics resistance/sensitivity to the oophoroma tumor patient.
Embodiment 2
Utilize generally acknowledged former chemotherapy sensitive cells of oophoroma patient (OV2008) of U.S. NCI (National Cancer Institute) and mdr cell (C13) (Yamamoto K; Deng: Heat shock protein 27wasup-regulated in cisplatin resistant human ovarian tumor cell line and associated with the cisplatin resistance.Cancer Lett.2001,168:173-181; Xu G; Deng: Nodal Induces Apoptosis and Inhibits Proliferation in Human Epithelial Ovarian Cancer Cells via Activin Receptor-Like Kinase 7.The Journal of Clinical Endocrinology & Metabolism 2004.89 (11): 5523-5534); Adopt immunofluorescence to detect (immunofluorescence IF); Immunohistochemical reaction (IHC) and Western Blotting improved method (.Perlecan domain V is neuroprotective and proangiogenic following ischemic stroke in rodents.J Clin Invest.2011Jul 11.pii:46358.doi:10.1172/JCI46358 such as Lee B); Verified that ERCC2 is higher 2.49 times than mdr cell in sensitive cells with different expression and ERCC2 protein content in the mdr cell (C13) at former chemotherapy sensitive cells of oophoroma patient (OV2008).Obtained ERCC2 on all four result in chemotherapy sensitivity and resistance patient slices.
I. collection of specimens
Gather oophoroma former the chemotherapy sensitive cells OV2008 and former chemotherapy resistance cell of the oophoroma C13 of international gynecological tumor circle approval.The OV2008 cell comes from epithelium serous ovarian cancer patient (Andrews et al, Cancer Res 1985,45 (12 Pt 1): 6250-6253; Andrews et al:Cancer Chemother Pharmacol 1987; 19 (2): 149-154), be derived from external a plurality of months cultivation and screening (Andrews et al, the Cancer Res 1985 of OV2008 cell inferior 1uM cis-platinums up to a hundred with mdr cell and the OV2008/C13 chemotherapy is responsive; 45 (12Pt 1): 6250-6253); These cells are received in Canadian Chun doctor Peng (York University, Toronto Canada), and conventional cell in vitro was handled before cell was preserved: i.e. cellular incubation; Albumen is purified ,-20 ℃ of preservations.
II. sample pre-service comprises the steps:
1. cellular incubation:
(1) get the one bottle of cell that changes liquid the previous day, the trypsinization with 0.25 after observation of cell becomes circle under the mirror, adds the effect that the 1640 nutrient culture media 1ml that contain 10% hyclone stop pancreatin, and with capillary burette piping and druming, cell is processed suspension;
(2) take a morsel cell with the blue counting of 0.4% placenta, then cell suspension is diluted to 2 * 10
4Individual cell/ml;
(3) will dilute good cell suspension inoculation in 6 orifice plates, every hole 2ml;
(4) insert in 37 ℃ of 5%CO2 incubators and to cultivate 48 hours.
2. albumen is purified:
(1) cell quantity: 6 porocyte culture plates, two every group parallel hole cell extraction albumen;
(2) lysis: with 50mM Tris-HCL PH6.8,2%SDS, 10% glycerine, 1mM PMSF (existing) lysate with add at present, every hole adds the abundant cracking 10～30min of 40 μ l lysates on ice;
(3) the centrifugal 10min of 14000rpm sucts clearly;
(4) BCA kit measurement protein concentration, and be sub-packed in the Ep pipe-70 ℃ of preservations with 30ug.
III.Western Blot detects
1. SDS-PAGE electrophoresis: 5% concentrates glue 100V, 10% separation gel 120V electrophoresis;
2. adopt the NC film, BIO-RAD changes the wet 200～250mA of commentaries on classics of film appearance 45min;
3. the sealing of 5% milk powder room temperature is 1 hour;
4. antibody incubation: anti-(ERCC21: 500, β-actin 1: 1000) 4 ℃ spends the night; Precooling PBST (containing 0.5 ‰ tween-20) washes 10min * 3; Two anti-1: 5000 room temperature 1h; Precooling PBST (containing 0.5 ‰ tween-20) washes 10min * 3;
5. ECL chemiluminescence: luminescence reagent A, B liquid equivalent (0.125ml/cm
2Film) mixes, be added in incubated at room 5min on the film, inhale behind the 5min and remove unnecessary liquid; Wrap with preservative film, put into X-ray magazine exposure (time shutter, the back band was strong and weak according to developing decides), show obvious band in the developer solution after; Tap water cleans; Stop bath photographic fixing 2～3min, the tap water flushing, room temperature is dried film.
6. gel images analysis: film being carried out digital photographing, carry out analyzing and processing through Lab works 4.6 softwares, is the relative density value that benchmark is analyzed each band with internal control gene β-actin.Its result is shown in accompanying drawing 2.A and Fig. 2 .B:
Can find out from Fig. 2 .A: the imaging gray scale of contrast marker protein β-actin two groups of cells is similar; But oophoroma sensitive cells OV2008 is stronger than the imaging gray scale of ovarian cancer drug-resistant cell C13; Thickness is wide, shows that the protein content of ERCC2 is higher than mdr cell in the oophoroma sensitive cells.
Use Excel and SPSS 10.0 softwares and map and statistical study, Fig. 2 .B display analysis is the result prove: the protein content of ERCC2 is higher than 2.49 times in ovarian cancer drug-resistant cell (C13) in oophoroma sensitive cells (OV2008).
IV. immunofluorescence detects:
1. solvent and compound method
I is anti-: ERCC2 (ProteinTech, Catalog No:101818-1-AP)
Fluorescence II is anti-: FITC mark goat anti-rabbit igg (middle China fir Golden Bridge, Catalog No:ZF-0311)
OLYMPUS is inverted and differs fluorescent microscope (Japan, OLYMPUS IX71)
2. Immunofluorescence Reactions
(1) OV2008 and C13 cell are used 0.25% trypsinization, be diluted to 2 * 104/ml and be inoculated in six orifice plates, every hole 2ml cell suspension;
(2) treat that cell 24 hours is adherent after, with fixing 10 minutes of 4%PFA (paraformaldehyde);
(3) PBS washes 5min * 3;
(4) confining liquid (containing 10% sheep blood serum, 30% seralbumin) sealing 1h;
(5) anti-(ERCC21: 150 of the I of confining liquid preparation; ProteinTech, Catalog No:101818-1-AP) 4 degree incubated overnight;
(6) PBS washes 5min * 3;
(7) FITC mark II is anti-[1: 50; FITC mark goat anti-rabbit igg (middle China fir Golden Bridge, Catalog No:ZF-0311)] lucifuge hatches 1h;
(8) PBS washes 5min * 3;
(9) the OLYMPUS inversion differs fluorescent microscope (Japan, OLYMPUS IX71) and observes, takes the photograph sheet.
V. immunohistochemistry detects:
1. solvent and compound method
Described solvent compound method of this method and embodiment 1 said solvent and compound method thereof are identical.
2. immunohistochemical reaction
(1) OV2008 and C13 cell are used 0.25% trypsinization, be diluted to 2 * 104/ml and be inoculated in six orifice plates, every hole 2ml cell suspension;
(2) treat that cell 24 hours is adherent after, with fixing 10 minutes of 4%PFA (paraformaldehyde);
(3) PBS washes 5min * 3;
(4) confining liquid (containing 10% sheep blood serum, 30% seralbumin) sealing 1h;
(5) antigen-antibody reaction:
I. anti-hatching: on cultured cells, add the ERCC2 antibody of 150 μ l,, clean 3 times each 10 minutes then with PBS in 4 ℃ of incubated overnight according to 1: 100 dilution proportion;
Ii two anti-hatching: on cultured cells, add 150 μ l biotinylations, two anti-working fluids, incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
(6) on cell, drip horseradish enzyme labeling strepto-avidin working fluid (S-A/HRP), incubated at room 60 minutes, PBS cleans 3 times, each 10 minutes;
(7) DAB colour developing:
I. prepare the substrate mixed liquor: in the distilled water of 1ml pH value=7.0, add a reagent A, after mixing, each one is added dropwise to wherein with reagent B and reagent C, mix the substrate mixed liquor;
Ii colour developing: 150 μ l substrate mixed liquors are dripped on cell color development at room temperature 3～10 minutes, fully colour developing back tap water flushing cessation reaction;
(8) dyeing, dehydration, transparent, mounting: histotomy is immersed the haematine dye liquor 2 times, each 2 seconds; Handle 3 times each 5 minutes then with distilled water; Respectively handle 1 time each 1 minute more successively with 50% ethanol, 70% ethanol, 90% ethanol; Handle 2 times with absolute ethyl alcohol again, each 2 minutes, 1: 1 mixture process of xylene and absolute ethyl alcohol 1 time, 2 minutes, 100% xylene processing 2 times, each 2 minutes; Use gummy mounting at last, preserve;
(9) OLYMPUS is inverted and differs fluorescence microscope, takes the photograph sheet;
(10) immunofluorescence and immunohistochemistry testing result (shown in accompanying drawing 4)
Fig. 4-a, d are the oophoroma cultured cells without any dyeing; Fig. 4-b, e are the oophoroma cultured cells through the immunohistochemistry fluorescent dye, and show: ERCC2 obviously strengthens in the expression of former chemotherapy sensitive cells (OV2008), is strong green, and a little less than the expression very of former chemotherapy resistance cell (C13), is dirty-green.Fig. 4-c, f are the oophoroma cultured cells through immunohistochemical staining, and show: ERCC2 is dark brown in the expression of former chemotherapy sensitive cells (OV2008), obviously is better than the expression at former chemotherapy resistance cell (C13), is light brown.It is in full accord that this result and ERCC2 institute in chemotherapy sensitivity and resistance patient slices obtains the result.
Claims (8)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102660411A CN102435734A (en) | 2011-09-08 | 2011-09-08 | Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application |
| PCT/CN2011/079885 WO2013033933A1 (en) | 2011-09-08 | 2011-09-20 | Kit, process and use for measuring and evaluating sensitivity of ovarian cancer to primary chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011102660411A CN102435734A (en) | 2011-09-08 | 2011-09-08 | Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102435734A true CN102435734A (en) | 2012-05-02 |
Family
ID=45983897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011102660411A Pending CN102435734A (en) | 2011-09-08 | 2011-09-08 | Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN102435734A (en) |
| WO (1) | WO2013033933A1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106198996A (en) * | 2016-06-29 | 2016-12-07 | 大连医科大学 | Early diagnosis biomarker, test kit and the application thereof of minimal change nephropathy |
| CN106610434A (en) * | 2016-02-26 | 2017-05-03 | 弗雷米德生物医药技术（天津）有限公司 | ELISA detection kit for HPV16 type E7 protein |
| CN113774135A (en) * | 2021-09-17 | 2021-12-10 | 广东省人民医院 | Marker for predicting prognosis of high-grade serous ovarian cancer and application thereof |
| CN117741149A (en) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | Detection kit for folic acid receptor alpha of ovarian cancer cells and application of detection kit |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007028161A2 (en) * | 2005-09-02 | 2007-03-08 | The University Of Toledo | Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states |
| US20080026950A1 (en) * | 2004-02-24 | 2008-01-31 | Mitsubishi Rayon Co., Ltd. | Gene Relating to Estimation of Postoperative Prognosis for Breast Cancer |
| CN101153325A (en) * | 2006-09-28 | 2008-04-02 | 上海主健生物工程有限公司 | Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene ERCC2 etc. |
| CN101306158A (en) * | 2007-05-14 | 2008-11-19 | 河北以岭医药研究院有限公司 | Use of traditional Chinese medicine in preparing medicine for treating myocardial infarction |
| CN101354341A (en) * | 2007-07-27 | 2009-01-28 | 上海主健生物工程有限公司 | Reagent kit for detecting female tumor disease genetic susceptibility |
| CN101371261A (en) * | 2005-11-14 | 2009-02-18 | 纽约哥伦比亚大学理事会 | MRI Imaging Correlation Methods for Neurogenesis |
| CN101598731A (en) * | 2009-05-07 | 2009-12-09 | 陈志南 | An immunohistochemical diagnostic kit for tumor pathological diagnosis |
-
2011
- 2011-09-08 CN CN2011102660411A patent/CN102435734A/en active Pending
- 2011-09-20 WO PCT/CN2011/079885 patent/WO2013033933A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080026950A1 (en) * | 2004-02-24 | 2008-01-31 | Mitsubishi Rayon Co., Ltd. | Gene Relating to Estimation of Postoperative Prognosis for Breast Cancer |
| WO2007028161A2 (en) * | 2005-09-02 | 2007-03-08 | The University Of Toledo | Methods and compositions for identifying biomarkers useful in diagnosis and/or treatment of biological states |
| CN101371261A (en) * | 2005-11-14 | 2009-02-18 | 纽约哥伦比亚大学理事会 | MRI Imaging Correlation Methods for Neurogenesis |
| CN101153325A (en) * | 2006-09-28 | 2008-04-02 | 上海主健生物工程有限公司 | Reagent kit for detecting susceptibility of cancer of the lungs with SNPs of gene ERCC2 etc. |
| CN101306158A (en) * | 2007-05-14 | 2008-11-19 | 河北以岭医药研究院有限公司 | Use of traditional Chinese medicine in preparing medicine for treating myocardial infarction |
| CN101354341A (en) * | 2007-07-27 | 2009-01-28 | 上海主健生物工程有限公司 | Reagent kit for detecting female tumor disease genetic susceptibility |
| CN101598731A (en) * | 2009-05-07 | 2009-12-09 | 陈志南 | An immunohistochemical diagnostic kit for tumor pathological diagnosis |
Non-Patent Citations (4)
| Title |
|---|
| LIN K, YE D, XIE X: "Protein expression levels of excision repair cross-complementation group 1 and xeroderma pigmentosum D correlate with response to platinum-based chemotherapy in the patients with advanced epithelial ovarian cancer", 《INT J GYNECOL CANCER》 * |
| 候旭等: "MGMT、ERCC2基因对替莫唑胺治疗恶性胶质瘤耐药性的影响极其表达相关性", 《中华医学杂志》 * |
| 夏婷等: "切除修复交叉互补基因1（ERCC1）在卵巢癌中的研究进展", 《肿瘤学杂志》 * |
| 汤春辉等: "卵巢癌实体瘤ERCC2表达与肿瘤发生及耐药的关系", 《肿瘤研究与临床》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106610434A (en) * | 2016-02-26 | 2017-05-03 | 弗雷米德生物医药技术（天津）有限公司 | ELISA detection kit for HPV16 type E7 protein |
| CN106198996A (en) * | 2016-06-29 | 2016-12-07 | 大连医科大学 | Early diagnosis biomarker, test kit and the application thereof of minimal change nephropathy |
| CN113774135A (en) * | 2021-09-17 | 2021-12-10 | 广东省人民医院 | Marker for predicting prognosis of high-grade serous ovarian cancer and application thereof |
| CN113774135B (en) * | 2021-09-17 | 2024-03-08 | 广东省人民医院 | Group of markers for predicting prognosis of high-grade serous ovarian cancer and application thereof |
| CN117741149A (en) * | 2024-02-19 | 2024-03-22 | 卡秋(江苏)生物科技有限公司 | Detection kit for folic acid receptor alpha of ovarian cancer cells and application of detection kit |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013033933A1 (en) | 2013-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Decenzo et al. | Antigenic deletion and prognosis of patients with stage A transitional cell bladder carcinoma | |
| Swan et al. | Bone marrow core biopsy specimens in AL (primary) amyloidosis: a morphologic and immunohistochemical study of 100 cases | |
| KR101976219B1 (en) | Biomarker for breast cancer | |
| CN106885908A (en) | The detection kit of blood-serum P SMD4 albumen and its detection method and application | |
| CN1360211A (en) | Method for enhancing clinical specificity in detecting stage of tumor and its precursor by simultaneously measuring at least two different molecular labels | |
| CN108179134B (en) | Functionalized microfluidic chip based on EpCAM/PSMA double antibody and its preparation method and application | |
| CN111679072A (en) | Application of KDM6B protein in breast cancer prognosis assessment kits and diagnostic kits | |
| CN109187977A (en) | It is a kind of detect HER2 antigen different loci immunofluorescent reagent box and application | |
| CN110007082A (en) | Application of ICOSL protein in the preparation of breast cancer prognosis assessment kit | |
| Umemura et al. | Immunohistochemical evaluation of hormone receptors in breast cancer: which scoring system is suitable for highly sensitive procedures? | |
| Gantumur et al. | Hepatic stellate cell as a Mac‐2‐binding protein‐producing cell in patients with liver fibrosis | |
| Shi et al. | Application of GATA 3 and TTF‐1 in differentiating parathyroid and thyroid nodules on cytology specimens | |
| CN102435734A (en) | Primary Ovarian Cancer Chemotherapy Sensitivity Evaluation Kit and Its Application | |
| Jee et al. | Midkine concentrations in fine‐needle aspiration of benign and malignant thyroid nodules | |
| CN102803968A (en) | Esophageal cancer marker | |
| CN117310167B (en) | Application of protein AMOTL2 in preparation of endometrial cancer diagnosis marker | |
| CN108957004B (en) | Application of reagents for detecting the expression levels of H3K9me2 and H3K36me3 in the preparation of gastric cancer prognosis assessment kits | |
| US20120040361A1 (en) | Methods and compositions for detection of lethal system and uses thereof | |
| CN109709333B (en) | Application of H4K20, H3K9 and H3K36 trimethylation detection reagents in the prognosis evaluation of esophageal cancer | |
| CN109870579B (en) | Monoclonal antibody protection solution, preparation method and application thereof, reagent using monoclonal antibody protection solution and immunohistochemical kit | |
| CN111948395A (en) | Quadruple marker for diagnosing immune regulation subtype of triple negative breast cancer and application thereof | |
| CN111323604A (en) | A group of prognostic markers for cardiac adenocarcinoma and their applications | |
| CN112698033A (en) | Detection method and application of blood-borne exosome HER2 | |
| CN105785004A (en) | Application of cell cycle division associated protein 2 to diagnosis or prognosis of pancreatic cancer | |
| CN106990245B (en) | Detect application of the reagent of PITX1 expression quantity in preparing gastric cancer prognosis evaluation reagent kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20120502 |